-
Ladenburg Sets A New Buy Rating, $85 Target On Anadarko
Monday, December 19, 2016 - 11:31am | 300Read More...Ladenburg Thalmann launched coverage of Anadarko Petroleum Corporation (NYSE: APC) with a Buy rating and $85 price target, which implies potential upside of 20 percent and represents 175 percent proven reserve LV multiple. “We believe the premium valuation is warranted given its potential...
-
Cuban Opportunity: President Trump Vs. Castro's Death
Tuesday, December 13, 2016 - 1:19pm | 373Read More...Fidel Castro's death could renew investor attention to the Herzfeld Caribbean Basin Fund, Inc (NASDAQ: CUBA), a closed-end investment fund with direct exposure to the Caribbean Basin country. In a research report dated Tuesday, Jon Hickman of Ladenburg Thalmann suggested Castro's death could mark...
-
Legal Overhangs Keep Ladenburg Neutral On Neovasc Despite Positive Tiara Clinical Data
Wednesday, December 7, 2016 - 12:43pm | 332Read More...The market's bullish response to Neovasc Inc (US) (NASDAQ: NVCN)'s announcement that Boston Scientific Corporation (NYSE: BSX) was set to buy a 15 percent stake in the company was bolstered by a positive data release on Neovasc's Tiara mitral valve. Shares gained 70 percent over the trading day...
-
Repros Therapeutics Shares Rally Following Ladenburg Upgrade To Buy, Positive Data
Wednesday, November 16, 2016 - 11:43am | 299Read More...Shares of Repros Therapeutics Inc (NASDAQ: RPRX) climbed more than 8 percent in Wednesday’s pre-market hours after positive clinical data of Proellex led Ladenburg Thalmann to upgrade shares to Buy, with a $5.50 price target. Repros announced positive Phase 2b data for both its oral and...
-
XOMA Challenged With A 'Major Financing Overhang'
Tuesday, November 15, 2016 - 11:39am | 330Read More...XOMA Corp (NASDAQ: XOMA) appears to have a “significant financing overhang,” having reported net loss of $12.5 million during Q3:16 and ending the quarter with $20.6 million in cash. Ladenburg Thalmann’s Matthew L. Kaplan maintains a Neutral rating on the company. Q3 And Overhang...
-
Taser's Top Line Was Impressive And Investors Responding In Part, But Competition Concerns Remain
Thursday, November 10, 2016 - 11:05am | 340Read More...TASER International, Inc. (NASDAQ: TASR) reported robust Q3:16 results, with the revenue beating the estimate and the consensus. Ladenburg Thalmann’s Glenn G. Mattson maintains a Neutral rating on the company. Q3 Results Taser reported its Q3:16 revenue at $71.9 million, beating expectations...
-
Kindred Biosciences Is 'Setting The Pace In Animal Health Biologics'
Tuesday, November 1, 2016 - 11:25am | 295Read More...Ladenburg Thalmann’s Kevin DeGeeter believes Kindred Biosciences Inc (NASDAQ: KIN) has an attractive growth opportunity in biologic therapies for the treatment of companion animals. DeGeeter initiated coverage of the company with a Buy rating and price target of $7.50. Setting The Pace...
-
Chesapeake's 4-Prong Strategy To Reduce Debt And Kick-Start Growth
Friday, October 21, 2016 - 10:04am | 295Read More...Chesapeake Energy Corporation’s (NYSE: CHK) Analyst Day highlighted improvements from efficiency gains and bigger completions, Ladenburg Thalmann’s Michael C. Schmitz said in a report. He maintained a Neutral rating on the company, with a price target of $6. 4-Prong Strategy...
-
Ladenburg Thalmann Positive On TG Therapeutics Post Adjustments To GENUINE Study
Friday, October 14, 2016 - 11:17am | 311Read More...Ladenburg Thalmann reaffirmed its Buy rating and raised its target price by $2 to $28 on TG Therapeutics Inc (NASDAQ: TGTX) shares following its amendment to its cancer study, GENUINE. Under GENUINE, TG Therapeutics is studying Ublituximab in combination with Ibrutinib versus Ibrutinib alone in...
-
Analyst Upgrades Capitala Finance On Dividend Alignment, De-Risked Portfolio
Thursday, October 6, 2016 - 12:40pm | 307Read More...Ladenburg Thalmann upgraded Capitala Finance Corp (NASDAQ: CPTA) to Buy from Neutral following dividend realignment and portfolio diversification. Late September, Capitala cut its monthly dividend $0.13 from $0.1567, primarily driven by losses in the energy portfolio and spread compression. The...
-
Taser Could Soon Be Facing Increased Price Competition
Monday, October 3, 2016 - 9:26am | 359Read More...TASER International, Inc.’s (NASDAQ: TASR) competitor, VIEVU, has won the coveted NYPD camera contract worth $6 million. The five-year contract is for the delivery of 1,000 cameras, which would ramp over time to 5,000. Ladenburg Thalmann’s Glenn G. Mattson downgraded the rating on...
-
Ladenburg Thalmann Says Newly Merged Apple Hospitality REIT Could See Weakness Near Term
Friday, September 2, 2016 - 1:08pm | 368Read More...Ladenburg Thalmann reiterated its Sell rating and $13 price target on Apple Hospitality REIT Inc (NYSE: APLE), saying that the merger close and guidance revision could cause technical weakness in the coming days. Apple Hospitality completed its merger with Apple REIT 10 (AR-10) and simultaneously...
-
Ladenburg Thalmann Initiates Spire With A Neutral Rating, $69 Target
Friday, August 19, 2016 - 9:46am | 380Read More...Ladenburg Thalmann has initiated coverage of Spire Inc (NYSE: SR) with a Neutral rating and $69 price target, saying current valuation commensurate with fundamentals. St. Louis, Missouri-based Spire is a public holding company that provides natural gas and related services to areas of Missouri and...
-
Spark Energy Is A 'Pure Play Competitive Retailer'
Friday, August 19, 2016 - 8:31am | 355Read More...Ladenburg Thalmann has started coverage of Spark Energy Inc (NASDAQ: SPKE) with a Neutral rating and $27 price target, saying that "the company's unique ownership structure supports M&A activity as compared to traditionally-structured competitors." The Rating And Price Target "While SPKE has...
-
Medley's Growth Initiatives Are Already Priced Into The Stock
Wednesday, August 17, 2016 - 12:35pm | 180Read More...Ladenburg Thalmann downgraded Medley Management Inc (NYSE: MDLY) to Neutral from Buy on valuation. However, the brokerage raised its price target by $1.50 to $7.50, implying a potential return of 4 percent. Medley reported Q2 core EPS of $0.14, which missed Ladenburg forecast/consensus of $0.16...
